Harrington Scholar-Innovator Grant Program
The Harrington Scholar-Innovator Award recognizes physician-scientists throughout the U.S. whose research has the potential to change standard of care. The Award provides clinical research funding as well as non-financial support to selected investigators and their institutions to help bridge the gap between …
Erik Lium, PhD, Named Vice President of Mount Sinai Innovation Partners
March 31, 2014 – Erik Lium, PhD, a 16-year veteran with an extensive background in the academic, technology and medical sectors, has been named Vice President and Executive Director of Mount Sinai Innovation Partners, which facilitates the real-world application and commercialization of Mount Sinai …
Harlem Biospace – Biotech Venture Summer Associate
Harlem Biospace(Hb) is a biotech incubator for New York City offering affordable shared wet-lab space for early-stage biotech companies. We have built a centrally located lab outfitted with modern biotech equipment, host unique classes and events, and provide business support – creating …
DBV Technologies and Mount Sinai Hospital Enter Research Collaboration for Crohn’s Disease
February 18, 2014– DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergies, and the Icahn School of Medicine at Mount Sinai announced today that they entered into a research collaboration agreement to investigate the …
Mount Sinai Genetic Testing Laboratory Launches More Accurate Carrier Screening Test for Spinal Muscular Atrophy
February 11, 2014 – The Icahn School of Medicine at Mount Sinai today announced the launch of a more accurate carrier screening test for spinal muscular atrophy (SMA), one of the most common and severe autosomal recessive disorders. This new test will help prospective …
Repurposing Drugs for Alzheimer’s Disease and Related Dementias Request for Proposals (RFP)
Neurodegenerative diseases represent one of the most difficult classes of diseases for which to develop drugs, yet the need is great with nearly 36 million people currently suffering from Alzheimer’s disease and related dementias worldwide. There are many different pathways that influence …
Single microRNA powers motor activity: Findings have implications for treating severe treatment-refractory epilepsy, says Mount Sinai researcher
December 5, 2013 – New research from the Icahn School of Medicine at Mount Sinai shows that microRNA-128 is one of the strongest regulators of nerve cell excitability and motor activity, and that it does so by adjusting an entire neuronal signaling …
Berg and Icahn School of Medicine at Mount Sinai Announce R&D Partnership for Drug Discovery and Development
October 10, 2013 – Berg, a biopharmaceutical company committed to a data-driven, biological research approach and the Icahn School of Medicine at Mount Sinai announced today a pharmaceutical and diagnostic R&D partnership that will leverage the power of multi-omic biology and data …
Dual Therapeutics, a New Oncology Start-up, is Launched by BioMotiv and the Icahn School of Medicine at Mount Sinai
October 9, 2013 – BioMotiv, a drug development accelerator based in Cleveland, and the Icahn School of Medicine at Mount Sinai, based in New York, are announcing the formation of Dual Therapeutics, a company focused on producing therapeutics for prostate cancer, lung …
Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
September 10, 2013 – Mount Sinai Innovation Partners (MSIP), part of the Icahn School of Medicine at Mount Sinai, has granted an exclusive license to Plexcera Therapeutics, LLC to commercially develop recombinant human acid ceramidase (rhAC) to treat diseases caused by genetic or …